In our cHL cohort, the TGF-β pathway was enriched in responders, whereas the IFN-γ, TNF, and IL-6 signaling pathways predominated in poor responders (Fig. 2A,B). The gene discussed is TGFB1; the disease is classic Hodgkin lymphoma.